Real-world data on the use of certolizumab pegol for the treatment of moderate to severe plaque psoriasis: 1-year results from a prospective non-interventional cohort study

Real world data on the 1-year treatment of psoriasis with the use of certolizumab pegol in women of child-bearing potential

Treatment history and symptom severity in patients with moderate to severe plaque psoriasis being initiated on bimekizumab: Use during the 1st year of routine clinical practice

Association of EQ VAS with treatment benefits and patient-reported benefits in patients with moderate to severe psoriasis – data from the German national psoriasis registry PsoBest

Temporal impact of infection-related treatment emergent adverse events on patient-reported outcomes in patients with moderate to severe psoriasis – analysis of the German national registry PsoBest

Real-world patient characteristics and prior treatment history of bimekizumab patients in Germany

Bimekizumab response through 3 years in patients with plaque psoriasis who stopped and re-started treatment

Bimekizumab impact on cardiovascular inflammation markers in moderate to severe plaque psoriasis: Results from phase 3 trials

Bimekizumab 3-year safety and tolerability in moderate to severe plaque psoriasis: Long-term pooled analysis from five phase 3/3b trials

Bimekizumab 3-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials

Bimekizumab efficacy through 144 weeks in moderate to severe plaque psoriasis: Patient-reported outcomes from BE RADIANT

Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials

A matching-adjusted indirect comparison of the efficacy of bimekizumab and guselkumab at 52 weeks for the treatment of psoriatic arthritis

Bimekizumab Efficacy and Safety in Patients with Active Psoriatic Arthritis and Psoriasis: 52-Week Results from the BE OPTIMAL and BE COMPLETE Phase 3 Randomised, Placebo-Controlled Studies

Sustained efficacy and safety of bimekizumab in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: Results from the phase 3 BE COMPLETE Study and its open-label extension up to 1 year

Bimekizumab improves key patient-reported symptoms of axial spondyloarthritis including spinal pain and fatigue: Results from two phase 3 studies